Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
Oncologist. 2020 Jul;25(7):e1131. doi: 10.1634/theoncologist.2020-0230. Epub 2020 Apr 28.
This letter to the editor alerts oncologists to the importance of accurately defining benefit‐risk ratio during the COVID‐19 pandemic for patients with advanced‐stage cancer treated with chemotherapy after failure of first‐line and second‐line therapy.
这封给编辑的信提醒肿瘤学家,在 COVID-19 大流行期间,对于一线和二线治疗失败后接受化疗治疗晚期癌症的患者,准确定义获益-风险比非常重要。